Last $24.18 USD
Change Today +0.08 / 0.33%
Volume 145.4K
ABMD On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

abiomed inc (ABMD) Snapshot

Open
$24.14
Previous Close
$24.10
Day High
$24.61
Day Low
$24.07
52 Week High
01/10/14 - $30.77
52 Week Low
05/8/14 - $20.29
Market Cap
978.4M
Average Volume 10 Days
176.8K
EPS TTM
$0.27
Shares Outstanding
40.5M
EX-Date
--
P/E TM
90.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for ABIOMED INC (ABMD)

Related News

No related news articles were found.

abiomed inc (ABMD) Related Businessweek News

No Related Businessweek News Found

abiomed inc (ABMD) Details

ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP, a micro heart pump; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the Impella RP, a percutaneous catheter-based axial flow pump; and AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, it offers Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics; and AbioCor program. The company sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, the United Kingdom, and internationally. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.

511 Employees
Last Reported Date: 05/28/14
Founded in 1981

abiomed inc (ABMD) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $519.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.9K
Chief Operating Officer
Total Annual Compensation: $341.8K
Vice President and General Manager of Global ...
Total Annual Compensation: $297.0K
Senior Vice President of Global Product Opera...
Total Annual Compensation: $284.6K
Compensation as of Fiscal Year 2014.

abiomed inc (ABMD) Key Developments

Abiomed Inc. Appoints Ingrid Goldberg as Director of Investor Relations

Abiomed Inc. announced the appointment of Ingrid Goldberg, as Director of Investor Relations. Prior to joining Abiomed, Ms. Goldberg was a Vice President at Bank of America Merrill Lynch. During her 9 year tenure at the bank, Ms. Goldberg held positions of increasing responsibility on the Capital Markets, Sales and Trading teams.

Abiomed Inc. Announces Clinical Trial Results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP(TM) (Right Percutaneous) System

Abiomed Inc. announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP(TM) (Right Percutaneous) System. The clinical trial results demonstrated a survival rate of 73% in the overall patient population. RECOVER RIGHT was an FDA-approved, prospective, multicenter, single arm study designed to evaluate the safety and probable benefit of the Impella RP in patients with right ventricular failure (RVF) refractory to medical treatment and deemed to require hemodynamic support. The 30 patients enrolled in the RECOVER RIGHT trial were categorized into two patient cohorts. Cohort A included patients who developed RVF within 48 hours after implantation of a left ventricular assist device (LVAD). Cohort B examined patients who developed RVF within 48 hours of post-cardiotomy shock or post-acute myocardial infarction (AMI) shock. The primary endpoint was patient survival at 30 days, hospital discharge, or bridge to the next therapy. Overall, the survival rate was 73% in the entire population at 30 days. Cohort A showed a survival rate of 83.3% and Cohort B had a 58.3% survival rate at 30 days.

ABIOMED, Inc. Appoints Dr. Eric Rose as a Class II Director

ABIOMED, Inc. announced that on August 13, 2014, company's board of directors appointed Dr. Eric Rose as a Class II Director, to serve for a term expiring at next annual meeting of stockholders. To accommodate Dr. Rose's appointment, the size of Board of Directors was increased from seven to eight directors. Dr. Rose previously served as a member of company's Board of Directors from May 2007 to January 2012 and has served as a consultant to the company since January 2012.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABMD:US $24.18 USD +0.08

ABMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $15.26 USD +0.01
LeMaitre Vascular Inc $7.10 USD +0.08
Spectranetics Corp/The $31.00 USD +3.67
Thoratec Corp $26.59 USD +0.235
Volcano Corp $10.13 USD -0.25
View Industry Companies
 

Industry Analysis

ABMD

Industry Average

Valuation ABMD Industry Range
Price/Earnings 100.0x
Price/Sales 5.1x
Price/Book 5.7x
Price/Cash Flow 132.8x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABIOMED INC, please visit www.abiomed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.